<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981175</url>
  </required_header>
  <id_info>
    <org_study_id>H-040-005</org_study_id>
    <nct_id>NCT00981175</nct_id>
  </id_info>
  <brief_title>A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults</brief_title>
  <official_title>Randomised, Double-blind, Phase 2 Study of the Safety, Immunogenicity and Duration of Immunity of ChimeriVax™-JE, Live Attenuated Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration
      of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in
      adults.

      Objectives:

      Safety:

        -  Obtain safety and tolerability data of a single, fixed dose of ChimeriVax™-JE compared
           with a placebo in adult volunteers (≥ 18 to &lt;55 years) without prior Japanese
           encephalitis (JE) vaccination.

      Immunogenicity:

        -  Obtain data on the antibody response in adult volunteers following administration of
           ChimeriVax™-JE

        -  Assess the durability of the immune response in adult volunteers over 60 months
           following one or two doses of ChimeriVax™-JE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive ChimeriVax™-JE or diluent on Day 0 and diluent or ChimeriVax™-JE on
      Day 28. A subset of participants in each group will receive a booster dose of ChimeriVax™-JE
      at Month 6. Follow-up visits will occur at 12 and 24 months. Eligible participants will then
      enter the long-term immunogenicity follow-up period with visits at approximately 36, 48, and
      60 months after Day 0. No safety data will be collected in the long-term immunogenicity
      follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Injection Site Treatment Emergent Adverse Events Post-Vaccination With ChimeriVax™-JE or Placebo at Day 0 and Day 28, and Following a Booster of ChimeriVax™-JE at Month 6 in a Subset of the Study Population.</measure>
    <time_frame>Days 0 to 28 post-vaccination</time_frame>
    <description>Injection Site Treatment Emergent Adverse Events: Pain, Reaction Not Otherwise Specified (NOS), Erythema, Swelling, Bruising, Nodule, Pigmentation Changes, Pruritus were assessed in all participants for up to 28 days post-Vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed by a Booster Vaccine Dose.</measure>
    <time_frame>Month 6 pre- and post-vaccination</time_frame>
    <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and pre- and post-Booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.</measure>
    <time_frame>Month 12 post-vaccination</time_frame>
    <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at 6 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.</measure>
    <time_frame>Month 24 post-vaccination</time_frame>
    <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at month 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Treatment Emergent Adverse Events Recorded as Possibly, Probably, or Definitely Related to Study Treatment.</measure>
    <time_frame>Day 0 up to 28 post-vaccination</time_frame>
    <description>Treatment emergent adverse events were assessed in all participants receiving ChimeriVax-JE Vaccine, Diluent (Placebo), or Booster Vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Encephalitis</condition>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live attenuated Japanese encephalitis virus, then ChimeriVax diluent</intervention_name>
    <description>ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28</description>
    <arm_group_label>Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChimeriVax diluent, then Live attenuated Japanese encephalitis virus</intervention_name>
    <description>ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.</description>
    <arm_group_label>Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine</arm_group_label>
    <other_name>ChimeriVax™-JE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

        At entry:

          -  All aspects of the protocol explained and written informed consent obtained from the
             subject.

          -  Aged ≥ 18 to &lt; 55 years.

          -  In good general health, without significant medical history, physical examination
             findings, or clinically significant abnormal laboratory results.

          -  Subject must be available for the study duration, including all planned follow-up
             visits.

          -  Has the subject agreed to take the following precautions to avoid insect bites for 7
             days following vaccination: (a) wear long-sleeved shirts and trousers?; (b) apply
             N,N-Diethyl-meta-toluamide (DEET)-containing insect repellents?; (c) Sleep in screened
             enclosures?

          -  For female subjects of childbearing potential: Negative serum pregnancy tests. An
             efficacious hormonal (i.e., oral, implantable or injectable) or barrier method of
             birth control must be used at least 1 month before Screening and Month 6 and at least
             1 month after Day 28 and Month 6. These subjects will sign an agreement that birth
             control will be practised during the specified periods and will specify the method
             used. Female subjects unable to bear children must have this documented (e.g., tubal
             ligation or hysterectomy).

        For long-term immunogenicity follow-up period:

          -  Subject received an initial dose of ChimeriVax™-JE, has a baseline (Day 0) sample and
             at least one post-vaccination evaluable serological specimen for antibody analysis.

          -  All aspects of the Long-term Immunogenicity Follow-up Period explained and updated
             written informed consent obtained from the subject.

          -  In good general health, without significant medical history that may affect the
             efficacy endpoints or the ability to take blood samples.

        Exclusion Criteria :

          -  A history of vaccination to Japanese encephalitis (JE). Previous vaccination will be
             determined by history (interview of subject) and/or by reviewing the subject's
             vaccination card or other official documentation (either a history of or documentation
             of vaccination fulfils the criterion for exclusion).

          -  Known or suspected immunodeficiency (e.g., human immunodeficiency virus [HIV]
             infection, primary immunodeficiency disorder, leukemia, lymphoma), use of
             immunosuppressive or antineoplastic drugs (corticosteroids &gt; 10 mg prednisone, or
             equivalent, for more than 14 days in the last three months).

          -  Clinically significant abnormalities on laboratory assessment.

          -  Serious adverse reactions characterised by urticaria or angioedema to a prior vaccine.

          -  Transfusion of blood or treatment with any blood product, including intramuscular or
             intravenous serum globulin within six months of the Screening Visit or up to Day 56.

          -  Administration of another vaccine within 30 days preceding the screening visit or up
             to Day 56 (these subjects will be rescheduled for vaccination at a later date).

          -  Physical examination indicating any clinically significant medical condition.

          -  Body temperature &gt;38.1°C (100.6°F) or acute illness within 3 days prior to inoculation
             (subject may be rescheduled).

          -  Intention to travel out of the area prior to the study visit on Day 56.

          -  Seropositive to hepatitis C virus (HCV) or HIV or positive for hepatitis B (HBV)
             (antigen).

          -  Lactation or intended pregnancy in female subjects.

          -  Excessive alcohol consumption, drug abuse, significant psychiatric illness.

          -  A known or suspected physiological or structural condition that compromises the
             integrity of the blood-brain barrier (e.g., significant hypertensive cerebrovascular
             disease, trauma, ischemia, infection, inflammation of the brain).

        For long-term immunogenicity follow-up period:

          -  History of Yellow Fever or out of study JE vaccination or known flavivirus infection
             since receiving ChimeriVax™-JE vaccination on Day 0 or Day 28 (during double-blind
             treatment period of the study). Yellow Fever/JE vaccination or flavivirus infection
             will be determined by history (interview of subject) and/or by reviewing the subject's
             medical records. Please note subjects who were flavivirus positive at Day 0 will be
             allowed to enrol on the study.

          -  Participation in another JE clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Enoggera</city>
        <state>Queensland</state>
        <zip>4051</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <results_reference>
    <citation>Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, Aaskov J, McCarthy K, Kanesa-thasan N, Meric C, Reid M. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin. 2010 Dec;6(12):1038-46. Epub 2010 Dec 1.</citation>
    <PMID>21150279</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>April 5, 2011</results_first_submitted>
  <results_first_submitted_qc>April 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2011</results_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>Japanese Encephalitis Vaccines</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled and vaccinated from 14 April 2003 to 05 January 2004 at 1 clinical center in Australia.</recruitment_details>
      <pre_assignment_details>A total of 202 participants who met the inclusion/exclusion criteria were enrolled and vaccinated. A subset of the participants also received a booster vaccine at month 6. A report on all participants who received the primary and booster vaccination and the primary vaccination only are presented.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ChimeriVax™-JE Vaccine First, Then Placebo</title>
          <description>Participants received ChimeriVax™-JE vaccine on Day 0 and vaccine diluent (placebo) on day 28.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then ChimeriVax™-JE Vaccine</title>
          <description>Participants received vaccine diluent (placebo) on Day 0 and ChimeriVax™-JE vaccine on day 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Dose Vaccination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Booster Dose Vaccination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55">A sub-set of participants in the group received the booster ChimeriVax™-JE vaccine.</participants>
                <participants group_id="P2" count="43">A sub-set of participants in the group received the booster ChimeriVax™-JE vaccine.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ChimeriVax™-JE Vaccine First , Then Placebo</title>
          <description>Participants received ChimeriVax™-JE vaccine on Day 0 and vaccine diluent (placebo) on Day 28.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then ChimeriVax™-JE Vaccine</title>
          <description>Participants received vaccine diluent (placebo) on Day 0 and ChimeriVax™-JE vaccine on Day 28.</description>
        </group>
        <group group_id="B3">
          <title>Booster ChimeriVax™-JE Vaccine</title>
          <description>Participants received a booster dose of ChimeriVax™-JE vaccine at Month 6 Following vaccination with ChimeriVax™-JE vaccine and Diluent (Placebo) at Day 0 and Day 28</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="7.36"/>
                    <measurement group_id="B2" value="27.7" spread="8.25"/>
                    <measurement group_id="B4" value="26.9" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B4" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose</title>
        <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Immunogenicity was assessed in the Intent-to-Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>ChimeriVax™-JE Vaccine (Single or Primary)</title>
            <description>Outcome for all participants that received ChimeriVax™-JE vaccine on Day 0 or day 28.</description>
          </group>
          <group group_id="O2">
            <title>Booster ChimeriVax™-JE Vaccine</title>
            <description>Participants received ChimeriVax™-JE vaccine booster at month 6.</description>
          </group>
          <group group_id="O3">
            <title>No Booster Vaccine</title>
            <description>Participants did not receive a booster dose Chimerivax™-JE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Dose</title>
          <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28.</description>
          <population>Immunogenicity was assessed in the Intent-to-Treat Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRNT50 ≥ 10 [N = 197]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRNT50 ≥ 20 [N = 197]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed by a Booster Vaccine Dose.</title>
        <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and pre- and post-Booster vaccination.</description>
        <time_frame>Month 6 pre- and post-vaccination</time_frame>
        <population>Immunogenicity was assessed in the Intent to Treat Population pre- and post-booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>ChimeriVax™-JE Vaccine (Single or Primary)</title>
            <description>Outcome for all participants that received ChimeriVax™-JE vaccine on Day 0 or day 28.</description>
          </group>
          <group group_id="O2">
            <title>Booster ChimeriVax™-JE Vaccine</title>
            <description>Participants received ChimeriVax™-JE vaccine booster at month 6.</description>
          </group>
          <group group_id="O3">
            <title>No Booster Vaccine</title>
            <description>Participants did not receive a booster dose Chimerivax™-JE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed by a Booster Vaccine Dose.</title>
          <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and pre- and post-Booster vaccination.</description>
          <population>Immunogenicity was assessed in the Intent to Treat Population pre- and post-booster vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-booster PRNT50 ≥ 10 [N = 0, 98, 93]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-booster PRNT50 ≥ 10 [N = 0, 97, 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="NA">Participants did not receive treatment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-booster PRNT50 ≥ 20 [N = 0, 98, 93]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-booster PRNT50 ≥ 20 [N = 0, 97, 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="NA">Participants did not receive treatment</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.</title>
        <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at 6 month.</description>
        <time_frame>Month 12 post-vaccination</time_frame>
        <population>Immunogenicity was assessed in the Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>ChimeriVax™-JE Vaccine (Single or Primary)</title>
            <description>Outcome for all participants that received ChimeriVax™-JE vaccine on Day 0 or day 28.</description>
          </group>
          <group group_id="O2">
            <title>Booster ChimeriVax™-JE Vaccine</title>
            <description>Participants received ChimeriVax™-JE vaccine booster at month 6.</description>
          </group>
          <group group_id="O3">
            <title>No Booster Vaccine</title>
            <description>Participants did not receive a booster dose Chimerivax™-JE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion to Homologous ChimeriVax™-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.</title>
          <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at 6 month.</description>
          <population>Immunogenicity was assessed in the Intent to Treat Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRNT50 ≥ 10 [N = 0, 80, 76]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRNT50 ≥ 20 [N = 0, 80, 76]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.</title>
        <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at month 24.</description>
        <time_frame>Month 24 post-vaccination</time_frame>
        <population>Immunogenicity was assessed in the Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>ChimeriVax™-JE Vaccine (Single or Primary)</title>
            <description>Outcome for all participants that received ChimeriVax™-JE vaccine on Day 0 or day 28.</description>
          </group>
          <group group_id="O2">
            <title>Booster ChimeriVax™-JE Vaccine</title>
            <description>Participants received ChimeriVax™-JE vaccine booster at month 6.</description>
          </group>
          <group group_id="O3">
            <title>No Booster Vaccine</title>
            <description>Participants did not receive a booster dose Chimerivax™-JE vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion to Homologous ChimeriVax-JE Virus Strain After a Single Dose of Chimerivax™-JE and Placebo Followed or Not by a Booster Vaccine Dose at 6 Month.</title>
          <description>Assay by 50% Plaque Reduction Neutralization Test (PRNT50) Seroconversion: PRNT50 ≥ 10 and PRNT50 ≥ 20. Assessed in all participants who received ChimeriVax™-JE vaccine on Day 0 and Day 28 and followed or not by a booster vaccine dose at month 24.</description>
          <population>Immunogenicity was assessed in the Intent to Treat Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRNT50 ≥ 10 [N = 0, 70, 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRNT50 ≥ 20 [N = 0, 70, 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Injection Site Treatment Emergent Adverse Events Post-Vaccination With ChimeriVax™-JE or Placebo at Day 0 and Day 28, and Following a Booster of ChimeriVax™-JE at Month 6 in a Subset of the Study Population.</title>
        <description>Injection Site Treatment Emergent Adverse Events: Pain, Reaction Not Otherwise Specified (NOS), Erythema, Swelling, Bruising, Nodule, Pigmentation Changes, Pruritus were assessed in all participants for up to 28 days post-Vaccination.</description>
        <time_frame>Days 0 to 28 post-vaccination</time_frame>
        <population>Injection site reactions were assessed in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>ChimeriVax™-JE Vaccine</title>
            <description>Participants received a primary dose of ChimeriVax™-JE vaccine at either Day 0 or Day 28</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaccine</title>
            <description>Participants received a dose of placebo vaccine (diluent)at either Day 0 or Day 28</description>
          </group>
          <group group_id="O3">
            <title>Booster ChimeriVax™-JE Vaccine</title>
            <description>Participants received a booster dose of ChimeriVax™-JE vaccine at Month 6 Following vaccination with ChimeriVax™-JE vaccine and Diluent (Placebo) at Day 0 and Day 28</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Injection Site Treatment Emergent Adverse Events Post-Vaccination With ChimeriVax™-JE or Placebo at Day 0 and Day 28, and Following a Booster of ChimeriVax™-JE at Month 6 in a Subset of the Study Population.</title>
          <description>Injection Site Treatment Emergent Adverse Events: Pain, Reaction Not Otherwise Specified (NOS), Erythema, Swelling, Bruising, Nodule, Pigmentation Changes, Pruritus were assessed in all participants for up to 28 days post-Vaccination.</description>
          <population>Injection site reactions were assessed in the Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Reaction NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Nodule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Pigmentation Changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Treatment Emergent Adverse Events Recorded as Possibly, Probably, or Definitely Related to Study Treatment.</title>
        <description>Treatment emergent adverse events were assessed in all participants receiving ChimeriVax-JE Vaccine, Diluent (Placebo), or Booster Vaccination.</description>
        <time_frame>Day 0 up to 28 post-vaccination</time_frame>
        <population>Treatment emergent adverse events were assessed in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>ChimeriVax™-JE Vaccine</title>
            <description>Participants received a primary dose of ChimeriVax™-JE vaccine at either Day 0 or Day 28</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaccine</title>
            <description>Participants received a dose of placebo vaccine (diluent) at either Day 0 or Day 28</description>
          </group>
          <group group_id="O3">
            <title>Booster ChimeriVax™-JE Vaccine</title>
            <description>Participants received a booster dose of ChimeriVax™-JE vaccine at month 6 following primary ChimeriVax™-JE and Diluent vaccination at Day 0 and Day 28</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Treatment Emergent Adverse Events Recorded as Possibly, Probably, or Definitely Related to Study Treatment.</title>
          <description>Treatment emergent adverse events were assessed in all participants receiving ChimeriVax-JE Vaccine, Diluent (Placebo), or Booster Vaccination.</description>
          <population>Treatment emergent adverse events were assessed in the Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Reaction Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lethargy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral Infection Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Function Test Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper Respiratory Tract Infection NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Nodule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pigmentation Changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroenteritis Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharygolaryngeal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Eyes Not Otherwise Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disturbance in Attention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flushing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from day of vaccination (Day 0) for up to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ChimeriVax™-JE Vaccine First , Then Placebo</title>
          <description>Participants received ChimeriVax™-JE vaccine on Day 0 and vaccine diluent (placebo) on Day 28.</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then ChimeriVax™-JE Vaccine</title>
          <description>Participants received vaccine diluent (placebo) on Day 0 and ChimeriVax™-JE vaccine on Day 28.</description>
        </group>
        <group group_id="E3">
          <title>Booster ChimeriVax™-JE Vaccine</title>
          <description>Participants received a booster dose of ChimeriVax™-JE vaccine at Month 6 Following vaccination with ChimeriVax™-JE vaccine and Diluent (Placebo) at Day 0 and Day 28</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Viral Infection Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection NOS</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="201"/>
                <counts group_id="E2" events="38" subjects_affected="35" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Viral Infection Not Otherwise Specified</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="201"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="199"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

